) Malignant brain tumors are highly lethal cancers. Despite considerable efforts at improving treatment through advances in neurosurgical technique, neuroimaging, radiotherapy, and chemotherapy, the overall prognosis of patients with malignant brain tumors remains grim. To improve outcome, coordinated clinical research is required to evaluate promising new treatment approaches. Laboratory studies of basic brain tumor biology are needed to develop more effective and better tolerated therapeutic strategies. The North American Brain Tumor Consortium (NABTC) was established four years ago for the broad purpose of stimulating cooperative efforts among multidisciplinary teams of clinical and laboratory researchers to improve treatment for patients with brain tumors. To accomplish the long term goal of developing more effective therapies for patients with brain tumors, we specifically propose to: 1. Share expertise with brain tumor clinicians and researchers in multiple disciplines. 2. Conduct joint Phase I and 11 clinical trials for patients with brain tumors, providing adequate patient populations for their timely completion. 3. Share brain tumor specimens and data that will be useful in the conduct of clinical pharmacologic and correlative laboratory studies. This proposal describes the neuro-oncology activities at the University of Pittsburgh, and reviews the resources available through the University of Pittsburgh Cancer Institute (UPCI), an NCI-designated Comprehensive Cancer Center, and the University of Pittsburgh Medical Center (UPMC), qualifying it for continuing participation in the North American Brain Tumor Consortium. The Central Operations Office/Coordinating Center for the NABTC will remain at the University of California, San Francisco. The UPCI and UPMC will provide essential support for all NABTC-related trials through such facilities as the General Clinical Research Center, the Clinical Core Facility, and the Tumor Tissue Bank. The University of Pittsburgh will collaborate with other members of the NABTC to rapidly evaluate new treatments by enrolling patients in Phase I and 11 NABTC clinical trials and to develop promising new therapeutic strategies through translational laboratory studies of brain tumor specimens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA062405-09
Application #
6489276
Study Section
Special Emphasis Panel (ZCA1-CRB-K (O1))
Program Officer
Wu, Roy S
Project Start
1994-03-18
Project End
2003-12-31
Budget Start
2002-01-01
Budget End
2003-12-31
Support Year
9
Fiscal Year
2002
Total Cost
$54,435
Indirect Cost
Name
University of Pittsburgh
Department
Neurology
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Vivanco, Igor; Robins, H Ian; Rohle, Daniel et al. (2012) Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2:458-71
Norden, Andrew D; Raizer, Jeffrey J; Abrey, Lauren E et al. (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96:211-7
Raizer, Jeffrey J; Abrey, Lauren E; Lassman, Andrew B et al. (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12:95-103
Raizer, Jeffrey J; Abrey, Lauren E; Lassman, Andrew B et al. (2010) A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol 12:87-94
Chang, Susan M; Lamborn, Kathleen R; Kuhn, John G et al. (2008) Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol 10:631-42
Lamborn, Kathleen R; Yung, W K Alfred; Chang, Susan M et al. (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-70
Prados, Michael D; Yung, W K A; Wen, Patrick Y et al. (2008) Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol 61:1059-67
Groves, Morris D; Puduvalli, Vinay K; Chang, Susan M et al. (2007) A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81:271-7
Cloughesy, Timothy F; Wen, Patrick Y; Robins, H Ian et al. (2006) Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24:3651-6
Cloughesy, Timothy F; Kuhn, John; Robins, H Ian et al. (2005) Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 23:6647-56

Showing the most recent 10 out of 17 publications